新闻

RapAdmin

WearableTech-2
WearableTech-22752×1536 502 KB

This is a position statement from the newly formed Wearable Technologies Special Interest Group of the European College of Sport Science, not a research study. Ten authors across eight countries survey where wearables have genuinely advanced physical activity, athletic training, sleep, and safety research, then catalog what is blocking further progress. Their diagnosis centers on four problems: consumer devices face no regulatory oversight for reliability or validity, output metrics are not standardized across brands, data from different devices and sources cannot easily be merged, and users lack the literacy to interpret what they are shown. A small survey of 61 ECSS members confirms these as the field’s top-rated frustrations.

The gap between what a wearable displays and what it actually measured is the central fact of consumer health technology, and almost nobody looks at it.

A ring tells you that you got 72 minutes of deep sleep. That number was not measured. What was measured was wrist or finger movement from an accelerometer and a light-absorption signal from a photoplethysmography sensor tracking blood volume changes. A proprietary algorithm, which the manufacturer does not publish and no independent group has fully evaluated, turned those two signals into a sleep stage. The number on the screen is a model output presented as an observation.

This position statement from the European College of Sport Science is, in effect, a group of people who validate these devices for a living saying out loud that the validation has not kept pace with the marketing.

Their survey of 61 members is small and informal, but the ranked complaints are telling. The top four are not about accuracy in the abstract. They are about cost limiting study size, output metrics not being standardized across brands, and the near-impossibility of merging data from different wearables or from wearables plus laboratory measures. These are the complaints of people trying to build a cumulative science out of devices designed to be consumer products. Two trackers worn on the same wrist measuring the same night will report different totals, and there is no agreed translation between them.

The regulatory point they make is the sharpest. A wearable is generally not classified as a medical device and is therefore not a diagnostic tool, which means it escapes the oversight that would apply to equipment making the same claims in a clinic. The authors propose that some authority, and they float IEEE, ISO, and the FDA without picking one, should certify device quality. They note that individual sports governing bodies have already built their own certification schemes because the general case was never solved. FIFA certifies tracking systems. FIBA certifies equipment. World Rugby certifies instrumented mouthguards and mandated them in elite competition in 2024. Everyone is building their own regulator because there is no shared one.

The group is asking for the right things: open programming interfaces, standardized formats, educational resources, real-world trials rather than laboratory ones. They are also asking to be the body that does the assessing, while simultaneously inviting industry partners and insurance companies into the collaboration. That is not a scandal. It is a governance question the paper does not raise about itself.

Actionable Insights

Translating this into what you should and should not act on from your own device.

Sleep or awake: trust it. Six popular devices (Apple Watch S6, Garmin Forerunner 245, Polar Vantage V, Oura Gen 2, WHOOP 3.0, Somfit) agreed with laboratory polysomnography on 86 to 89 percent of 30-second epochs when simply deciding sleep versus wake. Total sleep time and bedtime consistency are usable numbers.

Sleep stages: do not trust them. The same devices agreed with the laboratory on only 50 to 65 percent of epochs when assigning a specific stage. Worse, the chance-corrected agreement (Cohen’s kappa) for the two-state task ranged from 0.30 for Apple Watch to 0.51 for Oura. Kappa corrects for the fact that most epochs are sleep, so a device that guessed “asleep” constantly would still score high on raw agreement. A kappa of 0.30 is poor. Chasing a deep sleep number is chasing algorithm noise.

Activity trackers do change behavior, modestly. An umbrella review of 39 systematic reviews covering 163,992 people found standardized effects of 0.3 to 0.6 for physical activity, equating to roughly 1,800 extra steps per day and 40 minutes more walking, with about 1 kg of weight loss. Downstream effects on blood pressure, cholesterol, and HbA1c were small and often not statistically significant.

HRV-guided training: real, narrow. Across 8 studies and 198 participants, guiding endurance training by morning HRV produced a medium effect on submaximal physiological markers (Hedges’ g 0.296, 95% CI 0.031 to 0.562) but nothing significant on performance (g 0.079) or VO2peak (g 0.171). It changes how you adapt, not how fast you go.

Context and Source

RapAdmin

RichardMillerThinkingAboutAging-2
RichardMillerThinkingAboutAging-21920×1072 626 KB

In an opinion piece in The EMBO Journal, University of Michigan biogerontologist Richard Miller argues that seven widely held ideas are misdirecting aging research. In his view, aging has no single cause, “biological age” is not a real quantity, aging clocks cannot measure it, cultured cells do not age the way organisms do, cellular “rejuvenation” rests on shaky logic, biomarkers of age are being confused with measures of aging rate, the healthspan-versus-lifespan split is a false trade-off, and the Hallmarks of Aging framework discourages critical thinking. He proposes studying “aging rate indicators”: traits shared by young mice that are known to be aging slowly because of drugs, diets or mutations.

Few people have shaped mouse longevity research more than Richard Miller. As one of the lead investigators of the US National Institute on Aging’s Interventions Testing Program, he has spent two decades feeding candidate drugs to thousands of genetically diverse mice and recording when they die. In a new commentary in The EMBO Journal, he turns his attention from the mice to the scientists, arguing that much of the field is chasing ideas that collapse under careful thought.

His starting point is a definition. Aging, he insists, happens to a whole organism: it is the process that turns a healthy college sophomore into a 75-year-old with weaker muscles, worse hearing and a steadily rising risk of death. Cells in a dish do not age in that sense, and using one word for both has, in his view, sent researchers down blind alleys.

The first casualty is the hunt for a single cause of aging. Cancer, muscle loss, cognitive decline and weakened immunity each arise from tangled webs of contributing factors. Expecting one master cause behind all of them ignores what is already known.

Next is “biological age”, the idea that each person carries a hidden number that can be higher or lower than their birthday count. Miller compares this to merging someone’s talents for dancing, wine tasting and car sales into one “skilledness” score. Squashing many independent traits into one number throws away information.

Commercial aging clocks fare worse. Miller cites a 2023 study in which a transcription-based clock showed pregnant women aging rapidly and then growing younger after delivery, with similar reversible swings after emergency surgery and severe COVID-19. The authors read this as stress raising biological age. Miller’s reading: a watch that speeds up on a pregnant woman’s wrist and runs backward after the birth is simply a bad watch.

Cellular senescence, a hot commercial area, also takes a hit. Mouse telomeres are long and mouse cells do not senesce in culture the way human cells do, yet mice develop cancer, cataracts, deafness and cognitive decline much as people do. Apart from one unreplicated 2016 study, he says, no good evidence shows that clearing senescent cells extends lifespan, and the largest mouse trial of the senolytic fisetin found neither longer life nor fewer senescent cells.

He also rejects the fashionable stance that researchers should pursue healthspan but not lifespan. In mice, dogs and horses, longer-lived animals tend to stay healthier for longer. Health and longevity move like an elevator, not a seesaw.

His alternative is to stop comparing young and old animals and instead compare young animals that are known to be aging at different speeds, such as mice on rapamycin or restricted diets, or long-lived mutant strains. Traits shared across these unrelated slow-aging models could serve as a speedometer for aging rather than an odometer. They might also rescue human trials, which by his own calculation would need more than 1,100 volunteers to detect a drug that halves the yearly decline of a typical biomarker within one year.

This is an opinion essay, not a study, and many of its targets will push back. But its central warning, that a sophisticated-looking number is not a measured biological truth, applies to anyone paying for an aging test.

Actionable insights

  1. Be wary of judging a supplement with a clock. Miller’s worked example assumes a biomarker whose person-to-person spread (30 units) is three times larger than one year of aging change (10 units). A drug that halves the aging rate shifts the result by just 5 units in a year, an effect size of about 0.17 standard deviations. That is very small: you would need about 567 people per group to detect it reliably. With 50 per group, the chance of detecting a real effect is only 13% after one year. A single person’s before-and-after test cannot separate that signal from noise.
  2. Time any clock test away from illness, surgery or pregnancy. These events produced large, temporary swings in one published clock.
  3. Track function directly. Grip strength, lung function, contrast vision and hearing may be as informative as costly molecular tests, and you can repeat them cheaply.
  4. Discount senolytic claims for now. Fisetin did not extend lifespan in the most rigorous mouse test.
  5. Keep perspective on the mouse winners. Astaxanthin lengthened median male mouse lifespan by 12% and meclizine by 8%, with no significant benefit in females. There are no human lifespan data for either.

Context and source

  • Open Access Paper: Seven ways not to think carefully about aging, Published: 27 October 2026.
  • Author and institution: Richard A Miller, Department of Pathology and Paul Glenn Center for Biology of Aging, University of Michigan, Ann Arbor
  • Country: United States
  • Journal: The EMBO Journal (EMBO Press), published online 27 October 2026
  • Impact evaluation: The impact score of this journal is 8.7 (2025 JIF), evaluated against a typical high-end range of 0-60+ for top general science, therefore this is a High impact journal. It is a flagship society journal in molecular biology

相关阅读：

RapAdmin

GladyshevNewAgingTheory-2
GladyshevNewAgingTheory-22752×1536 471 KB

In his National Academy of Sciences inaugural article, Vadim Gladyshev of Brigham and Women’s Hospital and Harvard Medical School sets out a unified theory of aging. He argues that aging is the default result of imperfect biology. Every process in a living cell produces errors and by-products, and the leftover burden that repair, removal, and cell division fail to clear is what he calls the “deleteriome.” Aging is not programmed, there are no dedicated aging genes, and it starts after a natural rejuvenation in the early embryo. Aging clocks are useful but partial projections of this burden. Organs age at different rates. The most realistic near-term gains come from targeting each person’s weakest organ system and improving resilience. Breaking the species ceiling of roughly 120 to 150 years would need radical approaches such as reprogramming, regeneration, and organ replacement.

Biological aging resists a single mechanistic narrative. Researchers have long debated whether it is a programmed process, a loss of homeostasis, or the accumulation of molecular damage. A new unifying framework proposes that aging is simply the default outcome of living. Living systems operate under strict physical constraints and perform biological work imperfectly. These ongoing biological functions continuously generate errors, metabolic byproducts, and regulatory drift. Over time, this composite burden of deleterious changes accumulates into what is termed the deleteriome.

The deleteriome provides a cohesive way to view aging without reducing it to individual genes or isolated pathologies.Evolution does not program an organism to age. Instead, it selects for maintenance and renewal capacities that oppose deterioration, constrained by unavoidable energetic trade offs. Organisms naturally accumulate this residual burden because perfect damage clearance is biologically impossible for differentiated tissues. Aging officially begins early in development. Mammals experience a brief embryonic phase of rejuvenation that establishes a biological ground zero, the state of minimal damage. After this point, the deleteriome steadily rises, running in parallel with organismal development and maturation.

This perspective drastically shifts how clinical longevity interventions must be evaluated. Current biological aging clocks measure statistical projections of molecular states rather than the underlying deleteriome itself. While epigenetic and proteomic clocks provide useful proxies, they often conflate true age related damage with adaptive biological responses to that damage. Consequently, slowing aging requires more than superficially shifting an omic biomarker. It requires durably flattening the trajectory of functional decline across multiple distinct organ systems.

Organisms do not age uniformly. Different tissues accumulate deleteriome burden at different rates, creating localized states of accelerated aging that eventually manifest as distinct chronic diseases. Identifying and treating these distinct biological age patterns offers a highly effective route to increasing mean human lifespan. If interventions are applied universally, they fail to address the specific vulnerabilities of individual patients. A personalized diagnostic approach can identify an individual’s fastest aging organ system, their weakest physiological link, and target it with precise therapies before it triggers whole organism failure.

Maximal human lifespan features a soft limit dictated by our evolved systems level maintenance. Overcoming this ceiling demands more than lifestyle modifications or single drug regimens. Model organisms demonstrate that stabilizing system robustness decouples aging from mortality acceleration. For example, naked mole rats accumulate biological damage yet exhibit negligible Gompertzian mortality acceleration. Achieving similar outcomes in humans requires new classes of interventions. Long term strategies must explore partial cellular reprogramming, regeneration driven rejuvenation,heterochronic systemic modulation, and the targeted replacement of failing multiorgan systems. Until those radical technologies mature, the immediate medical imperative is to stabilize human physiological resilience and minimize the environmental fluctuations that transform accumulated biological burden into lethal clinical events.

Practical longevity depends on slowing the accumulation of the deleteriome and mitigating the failure of your fastest aging organ systems. Generic longevity protocols are suboptimal. Individuals must utilize multi system biomarkers to identify their specific physiological weak links, such as a rapidly aging kidney or cardiovascular system, and target therapies directly to that bottleneck before pathology develops.

The real world magnitude of optimizing this system level maintenance is substantial. The global mean lifespan is currently 73 years, yet populations with optimized environmental and lifestyle factors approach a mean lifespan of 90 years. This demonstrates a 17 year absolute effect size available through the reduction of lifelong deleterious exposures and the strengthening of baseline resilience. Furthermore, intrinsic human lifespan is up to 50 percent heritable. The remaining 50 percent variance is highly modifiable through actions that reduce damage flux, such as avoiding chronic overnutrition, minimizing avoidable toxins, and preserving robust repair systems through consistent aerobic and resistance exercise. Future interventions that effectively target individual organ ageotypes possess the potential to square the survival curve, moving the average biological failure point closer to the 120 year species ceiling.

Source and Context

  • Open Access Paper: Simply aging , (Published November 6, 2026).
  • Institution: Brigham and Women’s Hospital, Harvard Medical School Country: United States * Journal Name: PNAS
  • Impact Evaluation: The impact score of this journal is 11.1, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.

RapAdmin

PeakMidlifeFitness-2
PeakMidlifeFitness-22752×1536 441 KB

Researchers at Karolinska Institutet followed 427 Swedes born in 1958 from age 16 to 63, testing aerobic capacity, upper-body muscular endurance, and leg power at five points across 47 years. Every measure peaked between ages 19 and 36 and then declined along an accelerating curve, from under 1% per year in the early forties to more than 2% per year by the early sixties. By 63, participants had lost 30% to 48% of their peak capacity, a steeper fall than masters athletes typically show and larger than cross-sectional studies suggest. Men and women declined at similar rates after about 45. People who were active in their leisure time as teenagers stayed fitter throughout life, and switching from inactive to active at any age was linked to 4% to 11% higher performance. Activity shifted the whole curve upward but did not measurably change the timing of the peak or the slope of decline.

Most people assume their bodies start to fail somewhere around retirement. A Swedish study that tracked the same people for nearly half a century suggests the real turning point comes much earlier, around the age many of us are juggling careers and small children.

In 1974, researchers randomly selected 427 sixteen-year-olds from Swedish secondary schools. The same individuals were tested again at 27, 34, 52 and 63. Each round measured aerobic fitness on a stationary bike (or a timed run at 16), how many times they could press a light barbell, and how high they could jump. The result is one of the longest records of objectively measured fitness in an ordinary population anywhere.

The pattern is strikingly consistent. Aerobic capacity and upper-body endurance peaked in the late twenties to mid-thirties. Leg power peaked earliest, at 27 in men and as young as 19 in women. After the peak, decline began slowly, at less than 1% a year, then gathered pace, reaching about 2% to 2.5% a year by the early sixties. By 63, the typical participant had lost roughly a third of their aerobic capacity and upper-body endurance, and 41% to 48% of their jump height.

That trajectory mirrors what has long been seen in masters athletes, who also peak before 35 no matter how hard they keep training. The difference is depth. Lifelong competitors typically retain more than 80% of their peak endurance at 63; the Swedish general population retained about 65%. For leg power, ordinary 63-year-olds had already fallen to a level athletes usually don’t reach until their mid-seventies.

Two further findings stand out. First, people grow apart. Differences between the fittest and least fit participants widened dramatically with age, with the spread in body-weight-adjusted aerobic fitness increasing roughly 25-fold between 16 and 63. Aging amplifies whatever trajectory you are on. Second, the gap appears tied to habits. Teenagers who played sports in their free time stayed fitter for the next 47 years. More encouragingly, people who switched from inactive to active at any point scored 6% to 7% higher on aerobic tests, 11% higher on bench press endurance and 4% higher on jump height. A university degree was also linked to modestly better aerobic and endurance scores.

There are limits to what this study can say. Activity was recorded as a simple yes or no, so it cannot tell you how much or what kind of exercise matters. Being active lifted the whole curve but did not detectably change its shape: the peak arrived at the same age and the slope of decline was statistically similar. There was also an 18-year gap in testing between ages 34 and 52, so the precise moment decline begins is estimated by a statistical model rather than directly observed.

Still, the big idea is clear and useful. Peak fitness is set by biology and arrives early. How high that peak goes, and how much reserve you carry into your sixties, appears to be shaped by behavior, and it is never too late to start building it.

Actionable Insights

  1. Start now, whatever your age. Switching from inactive to active was associated with 6% to 7% higher aerobic capacity, 11% higher upper-body endurance and 4% higher leg power. At 63, when fitness was falling about 2.2% a year, a 6% aerobic edge is roughly equivalent to being 2.5 to 3 years younger, and the 11% endurance edge roughly 4 to 5 years younger. Put another way, becoming active offset about one-tenth to one-quarter of the total loss from peak to age 63. Real and worthwhile, but not a time machine.
  2. Build reserve in your 30s and 40s. Decline starts slowly and accelerates past 2% a year. Capacity banked early means more distance before you approach functional thresholds later.
  3. Train power, not only endurance. Jump height fell the most (41% to 48%), so include fast, explosive work such as jumps, sprints or quick sit-to-stands. This is inferred from the size of the loss, not tested directly.
  4. Watch body weight. Men gained about 24 kg between 16 and 52, which drags down per-kilogram fitness and jump height.
  5. Get children moving. Teen sports participation tracked with higher fitness for 47 years.

Context and Source

  • Open Access Paper: Rise and Fall of Physical Capacity in a General Population: A 47-Year Longitudinal Study
  • Institution: Karolinska Institutet and Karolinska University Hospital
  • Country: Sweden
  • Journal: Journal of Cachexia, Sarcopenia and Muscle (Wiley), 2025,
  • Impact evaluation: The impact score of this journal is approximately 9.7 (Journal Impact Factor; CiteScore approximately 14), evaluated against a typical high-end range of 0-60+ for top general science, therefore this is a High impact journal.

RapAdmin

ketoneInflammation-2
ketoneInflammation-21920×1072 613 KB

Aging is characterized by a progressive decline in immune function and a simultaneous increase in chronic, low-grade inflammation, largely driven by the accumulation of age-associated B cells. These cells contribute to autoimmune pathology by secreting pro-inflammatory cytokines and autoantibodies. This preclinical murine study investigated the immunomodulatory effects of a 15-week dietary intervention using the ketone ester bis-octanoyl (R)-1,3-butanediol. The dietary supplementation significantly increased circulating beta-hydroxybutyrate levels and suppressed the baseline activation of age-associated B cells in the spleen. Crucially, this metabolic intervention downregulated key inflammatory transcription factors and translation pathways without impairing the generation of antigen-specific antibodies following active immunization. The findings present a targeted metabolic strategy to separate pathological immune overactivation from necessary adaptive immune responses during biological aging.

The aging immune system presents a paradoxical challenge characterized by immunosenescence (the inability to mount effective responses to novel pathogens or vaccines) and inflammaging (chronic, systemic hyperactivation that damages native tissues). A primary driver of this dysfunction is the accumulation of age-associated B cells. In youth, these cells constitute approximately 5% of the splenic B cell population, but they expand nearly five-fold by late life, aggressively secreting pro-inflammatory mediators and autoantibodies that fuel degenerative pathologies.

While severe dietary interventions like prolonged fasting or strict ketogenic diets have shown efficacy in blunting this inflammatory cascade, compliance among older human populations remains exceedingly poor due to physical and metabolic demands. Exogenous ketone supplementation offers a bypass mechanism to achieve therapeutic circulating ketone levels without requiring absolute carbohydrate restriction. Researchers at the Buck Institute for Research on Aging utilized the specific ketone ester bis-octanoyl (R)-1,3-butanediol to evaluate its impact on the aged immune landscape.

Over a 15-week period, aged mice provided with the ketone ester diet demonstrated a highly specific phenotypic shift in their immune architecture. The intervention selectively downregulated activation markers (CD69 and CD95) on age-associated B cells while reducing their dependence on glucose metabolism. This effect is mediated by the signaling properties of beta-hydroxybutyrate, which acts directly on these cells to suppress the mTORC1 signaling pathway, thereby reducing abnormal cellular translation and halting the overexpression of T-bet, the master transcription factor responsible for the autoimmune behavior of age-associated B cells.

The most critical finding from a clinical and biohacking perspective is the precise selectivity of this intervention. Broad immunosuppressants typically resolve inflammaging at the cost of rendering the subject highly vulnerable to infection. However, when the ketone ester-treated mice were actively challenged with an immunization protocol, their adaptive immune systems successfully mounted a robust, high-affinity antibody response equivalent to that of the control group. This indicates that ketone esters do not universally cripple the immune system. Instead, they specifically quiet the baseline “noise” of chronic inflammation while leaving the functional machinery required for acute pathogenic defense entirely intact. This selective immunomodulation validates exogenous ketones as a highly pragmatic tool for managing the aging phenotype.

Actionable Insights

The continuous oral consumption of bis-octanoyl (R)-1,3-butanediol can elevate systemic beta-hydroxybutyrate to immunomodulatory levels without the need for strict ketogenic fasting protocols. For individuals focused on longevity, this suggests that incorporating specific exogenous ketone esters may successfully suppress chronic inflammatory pathways driven by senescent immune cells.

The practical magnitude of this intervention is notable. The dietary protocol successfully elevated circulating R-beta-hydroxybutyrate from near-zero baseline levels to a sustained range of 0.5 to 1.0 mM (an absolute increase reflecting a massive relative shift in metabolic environment). Consequently, flow cytometry data indicated significant reductions in CD69 and CD95 activation markers across the age-associated B cell population (p-values ranging from 0.001 to 0.028, representing robust statistical significance despite a small sample size of N=8 per group). The transition to a ketone-enriched state resulted in a measurable decrease in cellular glucose dependence and suppressed the mTOR-driven translation responsible for aberrant protein synthesis. For those aiming to mitigate autoimmune tendencies as they age, targeting a daily circulating beta-hydroxybutyrate level approaching 1.0 mM via ester supplementation represents a practical mechanism to blunt systemic inflammatory signals while preserving acute immune reactivity.

Context/Source

RapAdmin

HRTBrainImpactBenefits-2
HRTBrainImpactBenefits-22752×1536 506 KB

This study investigates the relationship between lifetime estrogen exposure and late life brain health in a cohort of 352 cognitively normal 70 year old women. Researchers analyzed endogenous estrogen, measured by reproductive lifespan, alongside exogenous estrogen from oral contraceptives and menopausal hormone therapy. Using magnetic resonance imaging, the team evaluated cerebral small vessel disease and Alzheimer disease related cortical thickness. The findings show that a longer reproductive span correlates with reduced small vessel disease burden. Furthermore, the combined use of oral contraceptives and menopausal hormone therapy is associated with significantly greater white matter integrity and a lower risk of severe small vessel disease. Although estrogen exposure did not globally prevent cortical thinning, menopausal hormone therapy preserved cortical thickness specifically in women carrying the APOE epsilon 4 genetic variant.

The trajectory of cognitive aging in women presents a distinct pattern compared to men, driven heavily by the fluctuations of sex hormones over a lifespan. Historically, research into female brain aging has concentrated on Alzheimer disease pathology, specifically the accumulation of amyloid and tau proteins. This paper redirects the focus toward the neurovascular system, proposing that estrogen acts as a primary guardian of cerebral blood vessels. The researchers evaluated a Swedish cohort of women to determine how both natural and synthetic estrogen shape the physical architecture of the aging brain.

The core finding is that cumulative estrogen exposure provides a durable shield against cerebral small vessel disease. Small vessel disease manifests as microscopic bleeds, enlarged perivascular spaces, and degraded white matter, all of which progressively restrict the brain’s metabolic supply and clearance networks. Women who experienced a longer natural reproductive span, defined as the time between first menstruation and menopause, exhibited a significantly lower burden of vascular damage at age 70. The data indicate that endogenous estradiol maintains the elasticity and integrity of the microvasculature, preventing the structural decay that frequently precedes cognitive decline.

Beyond natural estrogen, the study quantified the impact of pharmacological interventions. Oral contraceptives used during early adulthood and menopausal hormone therapy used during the menopausal transition both contributed to enhanced white matter integrity. Notably, women who utilized both oral contraceptives and menopausal hormone therapy throughout their lives demonstrated the highest structural brain health. This points to a cumulative physiological benefit. Exogenous hormones appear to sustain a neurovascular protective window, mitigating the abrupt withdrawal of estrogen that normally accelerates vascular aging during menopause.

The study found no universal protective effect of estrogen against Alzheimer disease cortical atrophy in the general population. The benefits were heavily restricted to the vascular plumbing of the brain. However, a critical exception involved genetic risk. Women carrying the APOE epsilon 4 allele, the strongest genetic risk factor for late onset Alzheimer disease, showed preserved cortical thickness if they had used menopausal hormone therapy. This finding suggests that hormonal interventions might specifically buffer the neurotoxic effects of the APOE epsilon 4 variant.

Ultimately, this research shifts the paradigm of hormonal therapy from a symptom management protocol to a potential strategy for lifelong neurovascular preservation. By maintaining the integrity of the brain’s microscopic blood vessels, continuous estrogen exposure likely supports glymphatic clearance and delays the cascading vascular failures that contribute to dementia. The data make a compelling case for viewing women’s brain health through a lifelong lens, where hormonal events in early adulthood and midlife collectively dictate structural resilience in later decades.

Actionable Insights

For individuals interested in longevity and neuroprotection, this study provides concrete data supporting the vascular benefits of hormone optimization. The primary actionable takeaway is that menopausal hormone therapy is not merely for alleviating vasomotor symptoms; it actively preserves the structural integrity of the brain’s white matter and vascular network. Women who used both oral contraceptives earlier in life and menopausal hormone therapy later in life experienced a 69 percent reduction in the odds of having severe small vessel disease, representing an odds ratio of 0.31. This represents a massive effect size for a pharmacological longevity intervention. Furthermore, combined hormone users exhibited a standardized fractional anisotropy increase of 0.45, indicating significantly superior white matter tract preservation.

For APOE epsilon 4 carriers, the data suggest that menopausal hormone therapy serves as a critical neuroprotective strategy. Hormone therapy users with this genetic variant showed a standardized cortical thickness increase of 0.38 in Alzheimer vulnerable regions compared to non users. Patients and clinicians should collaboratively weigh these substantial structural brain benefits against traditional risks when considering hormone therapy, viewing it as a long term investment in neurovascular span.

Context/Source

RapAdmin

ADHDMortalityRisks-2
ADHDMortalityRisks-22752×1536 509 KB

Attention-deficit hyperactivity disorder is highly correlated with adverse life outcomes and premature mortality. A comprehensive systematic review and meta-analysis of 19 studies encompassing over 15.9 million participants evaluated the association between this disorder and various mortality causes. The data demonstrate that individuals with this condition face a 71% elevated risk of all-cause mortality compared to control populations. This risk increase spans multiple specific causes, including an 89% increase in suicide risk, a 55% increase in fatal injuries, and a 27% increase in natural-cause mortality. Crucially, the meta-analysis reveals that pharmacological treatment for the disorder acts as a powerful protective intervention. Patients utilizing prescribed medication exhibit a 25% reduction in all-cause mortality risk. This underscores the critical importance of accurate diagnosis and sustained medical management for improving long-term health and survival.

Neurodevelopmental conditions are rarely viewed through the lens of classical longevity and lifespan extension. However, population data strongly suggest that psychological and neurobehavioral phenotypes exert a massive influence on mortality. The recent meta-analysis by Corrigan and colleagues aggregates data from nearly 16 million individuals across multiple nations to clarify the true magnitude of mortality risk associated with attention-deficit hyperactivity disorder. The findings reframe the condition from a behavioral or occupational impairment into a systemic risk factor for premature death.

The data reveal a stark reality. Individuals diagnosed with the disorder experience a hazard ratio of 1.71 for all-cause mortality. The elevated mortality is not driven solely by impulsive behaviors leading to accidents, although unintentional and intentional injuries are elevated by 55%. The risk profile is broad. Suicide rates are nearly doubled, reflecting the profound toll of co-occurring conditions like depression, anxiety, and the psychological burden of navigating environments poorly suited to neurodivergent individuals. Furthermore, natural-cause mortality is elevated by 27%, which highlights how the condition indirectly accelerates biological aging and physical decline. Poor impulse control and executive dysfunction frequently translate into adverse health behaviors, including higher rates of substance abuse, poor dietary choices, disrupted sleep architecture, and a failure to adhere to medical protocols for other chronic diseases. Over decades, these friction points compound, degrading metabolic and cardiovascular health.

The most critical finding from a life-extension perspective is the protective effect of pharmacotherapy. The analysis of medication users indicates a hazard ratio of 0.75 for all-cause mortality. This means that medical intervention fundamentally alters the survival trajectory of this population, pulling their mortality risk significantly closer to the baseline of the general public. The exact mechanisms of this mortality reduction likely involve acute improvements in impulse control and emotional regulation, which immediately reduce accident and suicide risks. Long-term benefits likely accrue from improved executive function, allowing individuals to maintain stable employment, cultivate supportive social networks, and reliably engage in positive health behaviors.

The scientific community must acknowledge that effective psychiatric treatment is a primary longevity intervention for affected populations. These findings strongly advocate for public health strategies that remove barriers to diagnosis and ensure continuous access to indicated medications. Addressing the structural determinants of health and reducing the stigma surrounding both the diagnosis and its pharmacological treatments will be necessary to close this substantial mortality gap.

Actionable Insights

For individuals with attention-deficit hyperactivity disorder, securing and adhering to evidence-based pharmacotherapy is one of the most statistically powerful actions available to increase lifespan. The data show a hazard ratio of 0.75 for medication use. In practical terms, this represents a 25% relative risk reduction in all-cause mortality.

The unmedicated condition carries a hazard ratio of 1.71. This means that over a given timeframe, an untreated individual faces a 71% higher chance of death from any cause compared to someone without the condition. Because the disorder increases natural-cause mortality by 27%, affected individuals must proactively optimize routine health behaviors. Executive dysfunction makes adherence to complex health regimens difficult. Therefore, biohackers and patients should prioritize automating their health routines. Strategies include using automated pill dispensers, subscribing to pre-prepared healthy meal deliveries, and utilizing digital scheduling systems to ensure consistent sleep patterns and medical appointments. By treating the underlying neurodevelopmental traits with medication, the cognitive friction associated with maintaining these healthy habits is significantly reduced, directly mitigating both the physiological and behavioral drivers of premature mortality.

Context/Source

RapAdmin

SmartWatchBloodPressure-2
SmartWatchBloodPressure-22752×1536 488 KB

Google researchers trained an AI model on wrist pulse waveforms (photoplethysmography) and motion signals from a Pixel Watch 3 to flag likely hypertension without any cuff calibration. In a prospective five-site US study, 196 adults without heart disease or blood pressure medication wore the watch for about a week and completed 24-hour ambulatory blood pressure monitoring, the clinical gold standard. The watch correctly flagged 66% of people with hypertension and correctly cleared 90% of those without it. A standard office reading caught 55% at the same specificity, but the difference was not statistically significant, and the overall accuracy of the two methods was nearly identical. Performance improved with wear time and leveled off at about an hour of usable data per day over five days. The system is meant as a screening prompt, not a diagnosis, and it was built and tested by the company that plans to sell it.

Roughly half of adults with high blood pressure have no idea they have it. The condition has no symptoms, and the standard way to find it, a cuff reading at a doctor’s office, is both infrequent and surprisingly unreliable. Office readings miss about half of people whose blood pressure is elevated across a full day, partly because some people relax in the clinic and spike everywhere else.

Google’s team took a different approach. Instead of trying to make a watch measure blood pressure directly, which has frustrated engineers for years, they asked a simpler question: does the shape of your pulse, recorded thousands of times over a week, carry a lasting signature of hypertension?

The watch’s green optical sensor records a pulse waveform with every heartbeat. Its accelerometer, during still moments, picks up the faint recoil of the body as the heart ejects blood into the aorta. The researchers first trained a neural network on nearly half a million hours of unlabeled watch data, teaching it to recognize what makes one person’s signals distinctive. They then trained a simple classifier to link those patterns to hypertension in 663 people who had worn a 24-hour blood pressure monitor.

The real test came in 196 new volunteers at five US sites, deliberately diverse in skin tone and age, and enriched for people with borderline readings. Each wore the watch for about a week, wore a 24-hour cuff monitor, took home readings, and had office readings taken. By the 24-hour standard, 39% had hypertension.

The watch caught 66% of them and wrongly flagged 10% of people without it. A single office visit caught 55% with the same false-alarm rate. Overall accuracy was essentially the same for both. The watch did better than a model using only age, sex and body mass index.

What the AI noticed fits known physiology. People it rated as high risk had pulse waves with a slower upstroke and altered reflected-wave timing, which are classic features of stiffer arteries. Their accelerometer traces showed a deeper dip corresponding to blood decelerating in the aorta.

The two methods also missed different people. About half the hypertensives missed in the office were caught by the watch. These are cases of so-called masked hypertension, which are especially easy to overlook.

There are important caveats. The study cohort had far more hypertension than the general population, which makes the device look more precise than it will be in everyday use. Almost all authors work for Google, which has already announced blood pressure features for its newer watches. The model has not been shown to track changes in blood pressure over time, so it cannot tell you whether a new diet or supplement is working. And because a third of the participants had already been flagged once, real-world sensitivity may be closer to the 50% seen during development.

Still, this is the first wrist-based hypertension screen validated against 24-hour monitoring rather than home cuffs. For people who never see a doctor, it could provide a nudge they would otherwise never get.

Actionable insights

The main message is that one normal office reading is weak reassurance. In this study, a single office visit missed 45% of people who were hypertensive over 24 hours. The watch missed 34%.

At matched false-alarm rates (10%), the watch caught about 8 more hypertensives per 76 than the office reading, a 10.5 percentage point gain. That gain was not statistically certain. Overall discrimination was similar: AUROC 0.856 for the watch versus 0.865 for office BP. Both correspond to a standardized separation of about 1.5, which is a large effect.

In a population where 20% have hypertension, a watch alert would raise your probability of having it from 20% to about 62%. No alert would lower it to about 9%. So an alert means “get a cuff,” and no alert does not mean “you’re fine.”

Practical steps:

  • If you are flagged, or if you want to rule out hypertension, do 7 days of home readings (morning and evening, seated, two readings each time) or a 24-hour ambulatory study. Home monitoring over 3 or more days had 89% sensitivity in this study’s subgroup.
  • Wear the watch at least an hour a day with good fit for 5 or more days; accuracy plateaued there.
  • Regarding the use of this feature to judge whether an intervention lowers your blood pressure. That has not been tested.

Context and source

  • Paywalled Paper: Opportunistically Detecting Signs of Hypertension on a Consumer Smartwatch
  • Institutions: Google Research (Cambridge MA, Mountain View CA, Seattle WA); University of Washington; Beth Israel Deaconess Medical Center/Harvard Medical School
  • Country: United States
  • Journal: Nature, published online 5 November 2026
  • Funding: Alphabet Inc.; 14 of 16 authors are Alphabet employees; patent application filed
    Impact evaluation: The impact score of this journal is 56.1 (Clarivate JIF 2025), evaluated against a typical high-end range of 0 to 60+ for top general science journals, therefore this is an Elite impact journal.

RapAdmin

NovosCoreVascularBenefits-2
NovosCoreVascularBenefits-22752×1536 460 KB

A six-month randomized, double-blind trial from the University of Surrey tested NOVOS Core, a daily 15 g powder combining twelve ingredients including glycine, calcium alpha-ketoglutarate, glucosamine, magnesium malate, fisetin, pterostilbene and low-dose lithium, in 61 healthy adults over 40. Among the 43 who finished, the supplement raised brachial flow-mediated dilation, a measure of how well arteries relax, by 2.9 percentage points more than placebo. It also reduced device-estimated pulse wave velocity by 1.18 m/s and lowered systolic blood pressure by 6.1 mmHg. Cholesterol and triglycerides did not change. Modeled 10-year cardiovascular risk fell by 0.45 percentage points, driven almost entirely by blood pressure. Effects appeared within one hour of the first dose. The trial was small, funded by the manufacturer, lost 30% of participants, and cannot say which ingredients matter.

Arteries age before people notice. Long before a heart attack or stroke, the inner lining of blood vessels loses its ability to release nitric oxide and relax, the aorta stiffens, and systolic blood pressure creeps upward. These three changes form the core of what cardiologists call vascular aging, and each predicts future cardiovascular events independently.

A team led by vascular physiologist Christian Heiss at the University of Surrey asked whether a supplement built on geroscience principles could push these markers in the right direction. The product, NOVOS Core, mixes twelve compounds that have each shown some anti-aging promise in worms, flies, mice or small human studies. The list reads like a longevity forum shopping cart: glycine, alpha-ketoglutarate, glucosamine, fisetin, pterostilbene, magnesium, vitamin C, L-theanine, Rhodiola, ginger, hyaluronic acid and a microdose of lithium.

Sixty-one healthy, non-smoking volunteers aged over 40 were randomly assigned to the powder or a taste-matched placebo for six months. The main measure was flow-mediated dilation, an ultrasound test that tracks how much the brachial artery widens after a cuff is released. Heiss’s lab is among the most experienced in the world at this test.

The results were significant. In people taking the supplement, artery dilation rose from about 5.5% to 8.1%, while the placebo group stayed flat. Systolic blood pressure dropped about 6 mmHg more than with placebo, roughly what a standard dose of a single blood pressure drug achieves. A device-based estimate of arterial stiffness also improved. Cholesterol did not budge.

Perhaps the most telling detail is timing. Artery function jumped within an hour of the very first dose, by an amount slightly larger than the six-month effect. That pattern suggests the product works mainly through a fast-acting effect on blood vessel tone that is renewed with each daily dose, rather than by slowly rebuilding aged arteries. The six-month measurements were taken about 24 hours after the last serving, so the study cannot tell lasting repair apart from lingering pharmacology.

There are good reasons for caution. Only 43 people completed the trial. The placebo group started out about five years older. The manufacturer funded the work, and one of its employees is a co-author. The effect on artery dilation is two to three times larger than what is typically seen with well-studied foods like cocoa flavanols or beetroot nitrate, and small trials with surprisingly large effects often shrink when repeated. The stiffness measure came from a cuff device that agrees poorly with the gold-standard method.

Still, the trial was properly randomized and blinded, the primary outcome was declared in advance, and the measurements came from a lab with a strong track record. If the blood pressure effect held up over years, large drug trials suggest it would cut heart attacks and strokes by around a tenth.

The next step is clear: a larger, independent trial with ambulatory blood pressure, gold-standard stiffness measurements and an attempt to identify which of the twelve ingredients is doing the work.

Actionable insights

For adults over 40 with normal to high-normal blood pressure, this trial suggests a specific daily blend may improve how arteries relax and modestly lower systolic pressure. The artery relaxation test improved by 2.9 points from a starting average of 5.5, about a 50% relative gain. In standardized terms that is a Cohen’s d of roughly 1.6, where anything above 0.8 counts as large. Treat that number with suspicion, since effects this big in small trials usually shrink on replication.

Systolic pressure fell about 6 mmHg more than placebo (d about 0.7, medium to large). Large drug-trial meta-analyses link each 5 mmHg drop to about 10% fewer heart attacks and strokes, so if sustained for years this could mean roughly 12% lower relative risk. In absolute terms, for a typical participant with 3% ten-year risk, that is about one event prevented per 220 to 280 people over a decade.

Practical steps: if you try this or any vascular supplement, take home blood pressure readings for two weeks before and after 8 to 12 weeks of use, since your own response is the most useful data you will get. Do not substitute it for prescribed medication. Expect no cholesterol benefit. Single ingredients with independent replication, such as magnesium, dietary nitrate and cocoa flavanols, remain reasonable lower-cost alternatives.

Context and source

  • Open Access Paper: Acute and 6-month vascular effects of a multi-component nutritional supplement: a randomized controlled trial
  • Institution: Faculty of Health and Medical Sciences, University of Surrey, Guildford, with Royal Surrey NHS Foundation Trust and Surrey and Sussex Healthcare NHS Trust; one co-author from NOVOS Labs, New York
  • Country: United Kingdom
  • Journal: European Heart Journal Open (European Society of Cardiology, Oxford University Press)
  • Funding: NOVOS Labs supplied product and placebo and made an unrestricted research contribution
  • Impact evaluation: The impact score of this journal is 4.3 (Clarivate JIF 2025), evaluated against a typical high-end range of 0 to 45+ for top cardiology journals (the flagship European Heart Journal sits near 45), therefore this is a Medium impact journal.

RapAdmin

IGF1DownCogSpeedUp-2
IGF1DownCogSpeedUp-22752×1536 500 KB

Researchers at Loyal Animal Health tested whether lowering insulin-like growth factor 1 (IGF-1) late in life changes how aged dogs think. Twenty-eight laboratory beagles aged 7 to 15, all experienced with cognitive testing, received a single injection of long-acting octreotide, a somatostatin analog that suppresses growth hormone, or saline. Octreotide cut circulating IGF-1 by about 29 percent at its peak, four weeks after dosing. Across three standard tests of attention, cognitive flexibility, and spatial working memory, treated dogs responded faster and were less likely to stall when task rules changed. They were not more accurate: correct answers, error counts, and memory scores were the same in both groups. The authors interpret this as improved processing efficiency and engagement.

Dogs, like people, slow down mentally as they age. Senior dogs take longer to choose, hesitate more when rules change, and are easier to distract. A new study from Loyal, a San Francisco company developing longevity drugs for dogs, asks whether a hormone that drives growth early in life might contribute to that slowdown later on.

The hormone is insulin-like growth factor 1, or IGF-1. Across worms, flies, and mice, animals with weaker growth hormone and IGF-1 signaling tend to live longer, and dwarf mice lacking growth hormone signaling keep their learning and memory skills deeper into old age. In dogs the pattern shows up across breeds: small breeds carry lower IGF-1 and live years longer than giant breeds. People with acromegaly, a condition of excess growth hormone, often have attention and memory problems.

To test the idea directly, the team took 28 laboratory beagles between 7 and 15 years old, all experienced at puzzle-box testing. Half received one intramuscular injection of long-acting octreotide, a drug used in people to treat acromegaly (high growth hormone levels). The other half got saline. Octreotide lowered blood IGF-1 by about 29 percent at its peak, four weeks after the shot, before levels began to rebound.

The dogs then worked through three classic tests. In one, they had to pick a familiar rewarded object while ignoring up to three decoys. In another, the reward rule was flipped so the object they had learned to ignore became the right one. In the third, they had to remember where a block had been after a delay of 20 or 90 seconds.

The treated dogs were quicker. With decoys present, they reached the correct object faster than placebo dogs. When the rules flipped, placebo dogs increasingly froze and made no choice at all, while treated dogs kept responding at their usual rate. In the memory task, treated dogs also responded faster, and the weakest performers appeared to gain the most.

What did not change matters just as much. Treated dogs were no more accurate in any test. They made the same number of errors, chose correctly at the same rate, and remembered locations no better. The authors themselves describe the result as better efficiency and engagement, not better memory.

That distinction leaves room for other explanations. A drug that alters gut hormones and digestion could change how hungry or alert a dog feels when food is the reward. The treated dogs were also already faster on the memory task before they received the drug, which weakens that result. With 14 dogs per group, one dose, and about six weeks of follow-up, the findings are early.

Still, the study offers something the field lacked: a randomized test of lowering IGF-1 in animals that are already old, rather than in mice engineered from birth. It suggests that dialing down this growth signal late in life does not blunt the aging brain in the short term, and may modestly speed it up. For Loyal, which is developing IGF-1-lowering drugs to extend the lives of large dogs, that is a useful early signal. Whether it translates into longer, sharper lives, in dogs or in people, is testing that is in process.

Actionable insights

The dog dose (about 0.9 mg per kg) converts on a body-surface basis to roughly 0.5 mg per kg in humans, around 34 mg for a 70 kg adult, which sits in the upper part of human acromegaly dosing.

How big was the benefit? In the distraction test, treated dogs got about 0.13 seconds faster than placebo dogs, roughly 13 percent of their starting response time. In standard terms that is a large effect (Cohen’s d about 0.9), but with only 14 dogs per group the true effect could plausibly be anywhere from trivial to very large. In the rule-switch test, placebo dogs stalled on about 7 more trials each, out of up to 200. On accuracy, the effect was zero.

The practical take-home is conceptual: modestly lower IGF-1 in late life did not harm cognition over six weeks, and may help. Keep in mind that very low IGF-1 is also linked to higher mortality in older adults, so the target is moderation, not suppression

Context and source

  • Open Access Paper: Octreotide treatment improves multiple domains of cognitive performance in aged beagle dogs
  • Institution: Loyal Animal Health, Inc., San Francisco, California. Animal work was approved by the InterVivo Solutions IACUC and followed Canadian Council on Animal Care guidelines, which indicates testing at a contract research facility in Canada [Confidence: Medium].
  • Country: United States (sponsor), Canada (probable testing site)
  • Journal: Frontiers in Veterinary Science (published 4 November 2026)
  • Impact evaluation: The impact score of this journal is 3.1, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Low impact journal.

#### Related Reading: